drug pricing

Pricing a new drug is not an easy task, Gilead who is producing remdesivir is no stranger to pricing controversy, the release of Solvaldi, their drug to cure Hepatitis C, had a list price of $84,000 for a full treatment course.

It is not surprising that pharmaceutical companies have filed a lawsuit seeking to block the implementation of the FDA’s new regulations regarding pricing information in direct to consumer (DTC) pharmaceutical advertising.

According to The Picture of Dorian Gray by Oscar Wilde, “there is only one thing in the world worse than being talked about, and that is not being talked about.”

I shouldn’t have been surprised—you can’t mention $2.125 million and expect people to just nod their heads and move on.

Physicians from across the political spectrum, from all over the country and representing nearly every specialty, came to Washington, DC earlier this week to advocate for and protect patients by shining a spotlight on the many hidden ways healthca

In addition to being a source of universal frustration, the high cost of drugs is a public relations nightmare for health systems and the much maligned pharmaceutical industry.

The U.S. Court of Appeals for the Federal Circuit just delivered another blow to a rather epic play by pharmaceutical giant Allergan to game the patent system.

Co-payments serve two purposes; first, they offset costs, well actually they add costs to you and reduce them for your insurer who never really "pays" for your care; and second, they make you think twice before you access your care.

Let the games begin.

What were the top selling prescription drugs last year? What segment of the population is most increasing its drug intake? What are the projections of medication spending in the next five years?